LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Articles
Orexigen Therapeutics Inc.
Headquarters:
La Jolla, CA, United States of America
Website:
N/A
Year Founded:
2003
Status:
Acquired
BioCentury
|
Sep 14, 2018
Finance
Coda’s chemogenetic control
Coda to bring chemogenetically activated gene therapy to the clinic with $19M
Read More
BioCentury
|
Sep 14, 2018
Financial News
MPM, Versant launch gene therapy play Coda
Read More
BioCentury
|
Sep 12, 2018
Financial News
MPM, Versant launch gene therapy play Coda
Read More
BioCentury
|
Aug 9, 2018
Company News
Management tracks: Grail, Celyad, Hua
Read More
BioCentury
|
Apr 27, 2018
Company News
Orexigen accepts $75M stalking horse bid
Read More
BioCentury
|
Mar 16, 2018
Financial News
Orexigen files for bankruptcy
Read More
BioCentury
|
Sep 21, 2017
Targets & Mechanisms
Appetite for GFRAL
Why pharmas think GFRAL could be the next obesity target
Read More
BioCentury
|
May 9, 2017
Politics & Policy
PhRMA revises eligibility criteria, cutting membership
Read More
BioCentury
|
Sep 13, 2016
Top Story
Competing drug pricing visions aired
Read More
BioCentury
|
Sep 5, 2016
Company News
Orexigen, Valeant Pharmaceuticals deal
Read More
Items per page:
10
1 - 10 of 298